Twist Bioscience Launches Rapid Turnaround, Customizable Panels to Advance R&D in Minimal Residual Disease (MRD) Detection in Cancer Screening
June 07 2022 - 7:00AM
Business Wire
-- Twist MRD Rapid 500 Panel Enables Customers
to Implement Fully Customizable Panels for $50 per Sample --
– Targets up to 500 Genomic Regions, Enables
Unmatched Response Time –
– MRD Testing Applications Include Cancer
Therapy Response Monitoring and Disease Surveillance –
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of the
Twist MRD Rapid 500 Panel1, a custom solution that can
be added to a standard next generation sequencing (NGS) workflow,
offering fully customizable and highly cost effective panels to
detect minimal residual disease (MRD) in as few as five days.
Twist’s customers develop MRD tests that can be used in a
variety of ways for patients with cancer. MRD testing is a
non-invasive method for tracking and predicting cancer progression
over time, using simple blood draws to track low levels of
circulating tumor DNA (ctDNA) in the blood. MRD testing can be used
during cancer treatment to determine if there are tumor cells
remaining and to assess whether a treatment plan needs to be
adjusted. This testing can also be used after a patient achieves
remission to monitor for recurrence of cancer cells.
“When it comes to monitoring minimal residual disease, which can
inform treatment options for patients with cancer, there is no time
to waste. With the Twist MRD Rapid 500 Panel, we are able to
rapidly create custom panels for our research customers, including
panels specific to each sample’s unique genetic variance of cancer
in as few as five days,” said Emily M. Leproust, Ph.D., CEO and
co-founder of Twist Bioscience. “MRD is becoming the gold standard
for monitoring cancer and informing personalized treatments for
patients. Through this panel, we facilitate the research and
development of our customers in developing new MRD solutions that
clinicians can use to benefit their patients.”
The Twist MRD Rapid 500 Panel can be incorporated into a
standard NGS workflow and applies hybrid capture technology to
sequence specific regions that may provide customized disease
insights to researchers. This technology provides broader coverage
than PCR or amplicon sequencing methods, potentially improving
sequencing sensitivity and expands utility.
To develop the custom panels, Twist receives targets of interest
that have been identified by the customer through sequencing
specific tumor cells. Twist then designs the probe sequence in a
single day, manufactures and ships the panel in five business days,
drastically reducing the waiting period typical of custom products
and enabling quick response times. The Twist MRD Rapid 500 Panel
leverages Twist’s existing protocols for target enrichment,
allowing it to be performed simultaneously with established Twist
whole exome NGS workflows.
About Twist MRD Rapid 500 Panel
The Twist MRD Rapid 500 Panel is the latest product in Twist’s
expanding portfolio of research use only sequencing products
dedicated to improving the performance and accessibility of
research tools for advancing R&D in oncology solutions. Paired
with Twist’s cfDNA pan cancer reference standards, UMI adapter
system, and leading Exome 2.0 product line, the Twist MRD Rapid 500
Panels bridge the gap between costly comprehensive sample screening
and small fixed content tests.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Twist Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Follow us on Twitter | Facebook | LinkedIn | YouTube
1 Twist NGS products are intended for research use only; not for
use in diagnostic procedures
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220607005477/en/
Angela Bitting Twist Bioscience (925) 202-6211
abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024